Literature DB >> 11981078

Comparison of blood group versus HLA-dependent transplantation and its influence on donor kidney survival.

Markus S Gillich1, Dirk Heimbach, Georg Schoeneich, Stefan C Müller, Hans Ulrich Klehr.   

Abstract

BACKGROUND: The advantages of organ allocation based on human leukocyte antigen (HLA) typing are controversial. This evaluation compares the results of HLA-dependent and non-HLA-dependent allocation in the transplantation of donor kidneys.
METHODS: Seventy-seven donor kidney pairs explanted locally between 1984 and 1994 were examined. One half of each pair was transplanted locally in Bonn on the basis of criteria including blood group, waiting time and currently negative cross-match. The other half of these pairs was allocated in accordance with the Eurotransplant (ET) criteria.
RESULTS: Cold ischaemia time was an average of 14.02 h in Bonn vs. 24.18 h in the ET group (P<0.0001). The number of HLA mismatches was calculated and, for example, for locus A it was 1.13 in Bonn vs. 0.73 in the ET group (P=0.0003). One-year graft survival for the locally transplanted kidneys was 92.2% and, for the ET kidneys, 90.9%. Five-year survival was 79.5% vs. 81.7%, respectively. Patient survival after 1 year was 100% vs. 97.4%, and after 5 years, 93.4% vs. 93.1%.
CONCLUSION: The results show that it is possible to provide patients with a locally allocated kidney graft that enables good function after a short waiting period. This procedure avoids long cold ischaemia time and long waiting periods.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981078     DOI: 10.1093/ndt/17.5.884

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  1 in total

1.  The use of personalized medicine for patient selection for renal transplantation: physicians' views on the clinical and ethical implications.

Authors:  Marianne Dion-Labrie; Marie-Chantal Fortin; Marie-Josée Hébert; Hubert Doucet
Journal:  BMC Med Ethics       Date:  2010-04-09       Impact factor: 2.652

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.